Literature DB >> 25190178

Pharmacovigilance: empowering healthcare professionals and patients.

Stephane Steurbaut1, Yolande Hanssens.   

Abstract

The European Union has thoroughly reformed its pharmacovigilance legislation in July 2012. Despite the changes, underreporting of adverse drug reactions remains a concern. This underreporting seems to be partially associated with incorrect customs and beliefs by healthcare professionals. Therefore, strengthening teaching and training in drug safety monitoring and reporting are essential. Sustained campaigns and education on pharmacovigilance are key elements to enhance its performance and effectiveness. In general, all healthcare professionals as well as patients should be more sensitized and empowered to contribute to pharmacovigilance programmes in order to improve drug safety.

Entities:  

Mesh：

Year:  2014        PMID： 25190178     DOI： 10.1007/s11096-014-0004-0

Source DB:  PubMed          Journal:  Int J Clin Pharm


  19 in total

1.  Underreporting of adverse drug reactions: attitudes of Irish doctors.

Authors:  D Williams; J Feely
Journal:  Ir J Med Sci       Date:  1999 Oct-Dec       Impact factor: 1.568

2.  Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region).

Authors:  Chiara Biagi; Nicola Montanaro; Elena Buccellato; Giuseppe Roberto; Alberto Vaccheri; Domenico Motola
Journal:  Eur J Clin Pharmacol       Date:  2012-06-17       Impact factor: 2.953

3.  Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region.

Authors:  Marta Irujo; Guadalupe Beitia; Maira Bes-Rastrollo; Adolfo Figueiras; Sonia Hernández-Díaz; Berta Lasheras
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 4.  Determinants of under-reporting of adverse drug reactions: a systematic review.

Authors:  Elena Lopez-Gonzalez; Maria T Herdeiro; Adolfo Figueiras
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.

Authors:  Joana Marques; Inês Ribeiro-Vaz; Altamiro Costa Pereira; Jorge Polónia
Journal:  Int J Pharm Pract       Date:  2013-11-05

6.  Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study.

Authors:  Francisca González-Rubio; Amaia Calderón-Larrañaga; Beatriz Poblador-Plou; Cristina Navarro-Pemán; Anselmo López-Cabañas; Alexandra Prados-Torres
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-06-23       Impact factor: 2.890

7.  First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.

Authors:  Geneviève Durrieu; Aurore Palmaro; Laure Pourcel; Céline Caillet; Angeline Faucher; Alexis Jacquet; Shéhérazade Ouaret; Marie Christine Perault-Pochat; Carmen Kreft-Jais; Anne Castot; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Journal:  Drug Saf       Date:  2012-10-01       Impact factor: 5.606

8.  The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist.

Authors:  Nicholas Moore
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

Review 9.  Under-reporting of adverse drug reactions : a systematic review.

Authors:  Lorna Hazell; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

10.  Toward enhanced pharmacovigilance using patient-generated data on the internet.

Authors:  R W White; R Harpaz; N H Shah; W DuMouchel; E Horvitz
Journal:  Clin Pharmacol Ther       Date:  2014-04-08       Impact factor: 6.875
View more
  5 in total

1.  Suspected adverse drug reactions (ADRs) trends in older Italian patients: an analysis from the National Pharmacovigilance Network.

Authors:  Gianluca Sferrazza; Giuseppe Nicotera; Pasquale Pierimarchi
Journal:  Aging Clin Exp Res       Date:  2019-08-19       Impact factor: 3.636

Review 2.  The value of patient reporting to the pharmacovigilance system: a systematic review.

Authors:  Pedro Inácio; Afonso Cavaco; Marja Airaksinen
Journal:  Br J Clin Pharmacol       Date:  2016-10-12       Impact factor: 4.335

3.  Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology.

Authors:  Paolo Baldo; Sara Francescon; Giulia Fornasier
Journal:  Int J Clin Pharm       Date:  2018-08-09

4.  The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study.

Authors:  Tim Schutte; Rike van Eekeren; Milan Richir; Jojanneke van Staveren; Eugène van Puijenbroek; Jelle Tichelaar; Michiel van Agtmael
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-10-23       Impact factor: 3.000

5.  Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland.

Authors:  J O'Callaghan; B T Griffin; J M Morris; Margaret Bermingham
Journal:  BioDrugs       Date:  2018-06       Impact factor: 5.807
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.